Synthesis of nanostructured powders and thin films of iron sulfide from molecular precursors

Iron(iii) xanthate single-source precursors [Fe(S₂COR)₃] (R = methyl, ethyl, isopropyl and 1-propyl) were used to deposit iron sulfide thin films and nanostructures by two simple, efficient and low-cost methods (spin coating and solid state deposition). The single-crystal X-ray structures of the iron(iii) n-propyl xanthate and iron(iii) iso-propyl xanthate have been determined. Thermogravimetric analysis (TGA) studies of the complexes shows that decomposition of the complexes produces iron sulfide, pyrite or trolite. The crystallinity of iron sulfide thin films and powder samples was studied using X-ray diffraction (XRD), and their morphology was studied by scanning electron microscopy (SEM).

Iron(iii) xanthate single-source precursors were used to deposit iron sulfide thin films and nanostructures by spin coating and solid state deposition.     

Population-based assessment of risks for severe COVID-19 disease outcomes

Among approximately 4.6 million members of Kaiser Permanente Northern California, we examined associations of severe COVID-19 with demographic factors and comorbidities. As of July 23, 2021, 16 182 had been hospitalized, 2416 admitted to an ICU, and 1525 died due to COVID-19. Age was strongly associated with hospitalization, ICU admission, and death. Black persons and Hispanic ethnicity had higher risk of death compared with Whites. Among the comorbidities examined, Alzheimer's disease was associated with the highest risk for hospitalization (aHR 3.19, CI: 2.88–3.52) and death (aHR 4.04, CI: 3.32–4.91). Parkinson's disease had the second highest risk of death (aHR = 2.07, CI: 1.50–2.87).     

BALAD and BALAD-2 predict survival of hepatocellular carcinoma patients: a North American cohort study

BackgroundThe BALAD score and BALAD-2 class derived from bilirubin, albumin, AFP, AFP-L3, and des-gamma-carboxyprothrombin (DCP) are effective in predicting mortality in HCC, but have not been validated in North America.Methods148 HCC patients from 2000 to 2015 who had all five biomarkers tested at diagnosis were included. Hazard ratios (HR) were calculated.Results75 patients died during a median follow-up of 21.9 months. 1-and 3-year survival rates were 70.8% and 47.6%. 114 (77%) had cirrhosis. The HR (95%CI) for death were 1.24 (0.42–3.67), 1.79 (0.61–5.26), 2.83 (0.95–8.38), and 7.19 (2.26–22.91) for BALAD scores 1, 2, 3, and 4 vs. BALAD 0. The HR (95%CI) for death were 1.25 (0.65–2.40), 1.75 (0.94–3.23), and 6.20 (3.29–11.68) for BALAD-2 classes 2, 3, and 4 vs. BALAD-2 class 1. A multivariate model incorporating maximal tumor diameter, tumor number, neutrophil-lymphocyte ratio, and BALAD had HR of 1.43 (1.14–1.81) per increase of 1 BALAD score. A similar model with BALAD-2 had HR of 1.50 (1.18–1.90) per increase of 1 BALAD-2 class.ConclusionBALAD models at diagnosis can predict the survival of HCC patients in North America. AFP, AFP-L3, and DCP reflect tumor progression and metastasis of HCC and distinguish the BALAD model from other predictive models.     

Improved Stability of Proline-Derived Direct Thrombin Inhibitors through Hydroxyl to Heterocycle Replacement

相似文献   

Correction to: Prognostic significance of serum inflammatory markers in esophageal cancer

Esophagus - In the original publication of the article, under the section “Clinicopathological characteristics”, the thresholds     

Adnexal lesions detected on CT in postmenopausal females with non-ovarian malignancy: do simple cysts need follow-up?

Abdominal Radiology - To assess whether CT morphology of adnexal lesions in postmenopausal women with history of non-ovarian cancer could be used to discriminate benign and malignant lesions,...     

Models used for case-mix adjustment of patient reported outcome measures (PROMs) in musculoskeletal healthcare: A systematic review of the literature

BackgroundCase-mix adjustment is an established method to take account of variations across cohorts in baseline patient factors, when comparing health outcomes. Although commonplace, there is a lack of evidence as to the most appropriate case-mix adjustment model to use to enable fair comparisons of PROM data in musculoskeletal services.ObjectivesTo conduct a systematic review summarising evidence of the development, validation, and performance of musculoskeletal case-mix adjustment models, and to make recommendations for future methods.Data SourcesSearches included; AMED, CINAHL, EMBASE, HMIC, MEDLINE, and grey literature.Eligibility CriteriaStudies; from January 1992-May 2017, English language, musculoskeletal adult population, developing or validating a case-mix adjustment model, using a relevant PROM, and using patient factors feasible for clinical collection.Data SynthesisTwo reviewers evaluated selected papers. The CASP Cohort Tool was used to assess quality.ResultsFourteen studies were included; eight US studies on the Focus on Therapeutic Outcomes model (pooled n = 546,726 patients (with pre/post treatment data)) and six UK studies related to the UK National PROMs Programme model (pooled n = 282,424 patients (with pre/post treatment data)). The majority used retrospective data, restricted to complete datasets. Both US and UK models showed good predictive ability (R2 18-42%). Common model variables were; baseline PROM score, age, sex, comorbidities, symptom duration, and surgical history. Reduced quality scores were mainly due to acceptability of patient recruitment, and completeness and length of patient follow up.ConclusionSignificant methodological crossover was found. Further studies are however needed to externally validate and develop models across musculoskeletal settings.PROSPERO database(CRD42017055948).